Shares in The Medicines Company (Nasdaq: MDCO) have been boosted by reports that Swiss drugmaker Novartis (NOVN: VX) is considering making a bid on the firm.
The reports come shortly after the release of detailed positive results from ORION-9, a key Phase III study of the novel siRNA candidate inclisiran, a biennial cholesterol-lowering therapy.
As well as a positive safety profile, the investigational treatment achieved a 50% reduction in LDL-C levels in people with heterozygous familial hypercholesterolemia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze